A Phase I/II Trial of TPI-287 in Patients With Refractory or Recurrent Neuroblastoma and Medulloblastoma.

Trial Profile

A Phase I/II Trial of TPI-287 in Patients With Refractory or Recurrent Neuroblastoma and Medulloblastoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs TPI 287 (Primary)
  • Indications Medulloblastoma; Neuroblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jan 2016 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 17 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Apr 2012 Planned End Date changed from 1 Nov 2014 to 1 Nov 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top